This way, CXCL13 and its ligand might contribute significantly to tumour formation, and therapeutic interventions aiming at interrupting CXCL13/CXCR5 interactions might be of benefit for the clinical course of patients with breast cancer. Here, CXCR5 is linked to neoplasm.